With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

Health care product distributor Henry Schein has redoubled its effort to provide in-kind donations and grants to disaster-stricken areas, as well as to work with NGOs to proactively supply vulnerable areas with medical and dental supplies—so supplies are there even if roads or airports become unusable. Its Global Product Donation Program has donated over $75 million in health care supplies to health centers and clinics since its 1998 inception. Henry Schein also provides $10,000 in cash grants and $25,000 in products through its Prepare to Care Program to each of five nonprofit partners committed to disaster-relief preparedness and immediate assistance in natural disaster-prone areas.

Change the World

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Henry Schein

As with many aspects of daily living, the standard dentist visit was not designed with much consideration for the needs of those with disabilities. For some, the experience may be physically inaccessible; for others, like those with developmental disabilities such as autism, the environment and experience—with its bright lights, buzzing noises, and close contact—can be terrifying and traumatic. Meanwhile, in part due to those challenges, people with disabilities suffer higher rates and more severe cases of periodontal disease, gum disease, and untreated cavities—all conditions that can lead to other health problems. Henry Schein, the dental and medical supply company, began work to address this disparity more than a decade ago, forging partnerships—like Project Accessible Oral Health—to increase training and adapt dental practices to better serve disabled people. The efforts have resulted in provision of specialized services to hundreds of thousands of children as well as a new dental school curriculum, developed with stakeholders like the American Dental Education Association.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

Founded by its namesake as a Queens, N.Y., pharmacy in 1932, the company is now one of the world's largest distributors of dental supplies and other medical goods, operating in more than 30 countries. An ever-present on Fortune's list of the <a href="https://fortune.com/worlds-most-admired-companies/">World's Most Admired Companies</a>, it is considered by many in its sector as a leader in social responsibility. With $10.1 billion in sales last year, Henry Schein moved up six spots on this year's Fortune 500 list.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020_304_Henry-Schein

Long Island's largest public company by revenue, Melville, N.Y.-based Henry Schein globally distributes medical and dental supplies including vaccines, pharmaceuticals, financial services, and equipment. The company kicked off 2019 by spinning out its animal health unit in an attempt to focus on its core medical and dental businesses; it ended the year with the novel coronavirus pandemic eroding its business.

As we face unprecedented collective challenges, cooperation has become a business superpower.

19.CTW20.21.Henry-Schein

Five years ago, well before COVID-19 entered the lexicon, Henry Schein CEO Stan Bergman called on his peers at the World Economic Forum to think collectively about pandemic preparedness. It worried him that there was no organized emergency product list, and no directory of where to get such products when emergency struck. Soon after, Bergman’s dental and medical supply company became a founder and the private-sector lead of the Pandemic Supply Chain Network, a public-private partnership whose members include the World Health Organization, the World Bank, UPS, and more than five dozen health care manufacturers. 
 
The group created a platform to convene responders and exchange information. Says Bergman: “You can’t do it in the middle of a pandemic. You’ve got to exchange business cards well before.” The network functioned well in recent Ebola outbreaks, and in response to COVID-19, it has sourced more than $200 million worth of critical supplies, like masks, gowns, and swabs, so far.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Change The World

Impact Segment

Sector

Prior Year Rank

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Henry Schein is a global health care services distributor of dental and medical supplies, business and supply-chain solutions, and tech-forward integrated care solutions. The nearly century-old company operates in over 30 countries and has developed more than 300,000 products, from diagnostics to surgical and orthopedics, including whitening strips, dental implants, patient communication services, and a dual-cuff blood pressure monitor. In early 2025 the company acquired Acentus, a national medical supplier of continuous glucose monitors, to expand its portfolio. Henry Schein has been named among the World’s Most Ethical Companies by Ethisphere for 13 consecutive years.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Henry Schein (HSIC): Company Profile, Stock Price, News, Rankings

legacy

Henry Schein

henry schein

Good morning, ladies and gentlemen, and welcome to Henry Schein's second quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session. Please press the star key, followed by one on your touch-tone phone if you'd like to ask a question at the end of the call. If anyone should require assistance during the call, please press the star key followed by zero on your touch-tone phone. As a reminder, this call is being recorded.

I would now like to introduce your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.

Thank you, operator, and my thanks to each of you for joining us to discuss Henry Schein's financial results for the second quarter of 2026. With me on today's call are Fred Lowery, Chief Executive Officer, and Ron South, Senior Vice President and Chief Financial Officer. Before we begin, I'd like to state that certain comments made during this call will include information that is forward-looking. Risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements.

The company's performance may materially differ from those expressed in or indicated by such statements. These forward-looking statements are qualified in their entirety by the cautionary statements contained in Henry Schein's filings with the Securities and Exchange Commission and included in the Risk Factors section of those filings. All comments about the markets we serve, including end market growth rates and market share, are based upon the company's internal analyses and estimates.

Today's remarks will include both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures. Reconciliations between GAAP and non-GAAP measures are included in Exhibit B of today's press release and can be found in the Financials and Filings section of our Investor Relations website under the Supplemental Information heading, and also in our quarterly earnings presentation, also posted on our Investor Relations website.

The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 4th 2026. Henry Schein undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Lastly, during today's Q&A session, please limit yourself to a single question so that we can accommodate questions for as many of you as possible. With that, I'd like to turn the call over to Fred Lowery.

Thank you, Graham. Good morning, everyone, and thank you for joining us. Let's dive right in. We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first quarter. This acceleration, combined with the strong gross margins and the early benefits from value creation initiatives, drove strong earnings growth.

Our first half performance and the sustained momentum have positioned us to raise our full year 2026 guidance. Ron will provide more details later in the call. Before we get into more detail on the quarter, I want to share some feedback from various stakeholders I've met in my first months here at Henry Schein, also some of my thoughts on why I'm confident in our opportunities ahead to accelerate growth. Our customers value the range of products and the integrated technology solutions we offer to support the growing complexity of operating a healthcare practice.

They see Henry Schein as a reliable business partner due to our consistent execution, our product quality, and our responsiveness. Our supplier partners also recognize our deep customer relationships, and they want to do more business with us, and our growth helps ensure we remain their partner of choice. In addition to customers and suppliers, I spent a lot of time talking with employees and shareholders who are optimistic about our plans to improve, including making decisions faster, simplifying how we operate, and executing more consistently for the benefit of our customers.

Henry Schein has great assets and capabilities and our customer reach is really unmatched. What's exciting is that after my first few months at the company, I have an increased conviction that there's significant opportunity to improve our revenue growth and improve our profitability, and ultimately become the platform to help healthcare practitioners operate a better practice. As we sharpen our focus, our priorities ahead are accelerating growth, simplifying our business, driving operational rigor, and further deepening our customer relationships, all of which we believe will create sustainable shareholder value.

With respect to accelerating growth, we're already pursuing several key initiatives to do more for our customers, and these initiatives are beginning to pay off. For example, we're advancing our Henry Schein One technology platforms, including AI-enabled solutions to improve workflows and collections, enhance practice performance, and strengthen patient engagement. This functionality is embedded in our Dentrix Ascend, and our data shows that customers who convert to Dentrix Ascend are seeing a clear improvement in their profitability.

June was a record month for the number of new Dentrix Ascend customers, growing both our customer base and capturing share of wallet. While our average monthly revenue per customer for Henry Schein One is approximately $500, our average monthly revenue for Dentrix Ascend customers is approximately $800. It's growing as customers recognize the value of the new integrated capabilities and upgrade to higher levels of functionality.

We're also accelerating our sales in our own brand products, including our corporate brands, by leveraging our One Schein approach and aligning our go-to-market strategies across the business. For example, in Endodontics, our Edge brand, which we started distributing through our U.S. dental distribution business last year, has very strong sales growth. We also have a leading position in the fast-growing DSO segment of the market, which is driven especially by the middle market segment.

As these DSOs continue to consolidate the dental market, this structural advantage should allow us to outgrow the broader dental market. Finally, we've expanded our medical business to attractive high growth areas, including our Home Health Solutions business, which grew sales in the high single digits last quarter. To simplify our business, we're taking an integrated versus a decentralized approach across several areas. For example, we are implementing shared service back-office functions globally and centralizing our indirect procurement.

We also need to make it easier for us to work with each other, as well as for our customers to work with us. We're eliminating internal silos and aligning individual incentives with broader company-wide goals. We're also evaluating our portfolio with a focus on businesses that drive higher growth and higher returns. Finally, we're driving operational rigor by delivering what we expect to be at least $200 million in operating income improvements from value creation initiatives over the next few years.

This is not just about the $200 million. It's about creating a high performance culture of accountability and continuous improvement while also increasing customer satisfaction. Complementing these efforts is a deliberate approach to capital deployment to ensure that resources are allocated to maximize long-term value. Across all of these efforts, a relentless focus on customer success will guide how we prioritize and how we execute. By helping customers operate more efficiently, making better decisions, and deliver better care, we can strengthen our relationships and further enhance our competitive position.

As a result, we expect to accelerate growth and expand our market share, deliver stronger financial performance, and create durable shareholder value. With disciplined execution and working smarter as one team, we expect to deliver a better customer experience and a more profitable business. Let's turn to the second quarter results. Our markets remain stable and durable and have good underlying fundamentals and a long runway for growth. We're not seeing a significant impact on patient volumes resulting from higher oil prices, and we believe the markets that we serve are resilient to economic pressure.

Our dental merchandise business was strong globally, and we made further gains in market share in the quarter. Our U.S. dental merchandise sales performance continued to outpace the market, led by our corporate brands and by our exclusive products such as Curadont. With our unique product offering, along with new sales reps, we are expanding our share of wallet and converting occasional buyers to actively engaged customers. Merchandise sales growth also accelerated internationally with markets like Canada standing out.

In Canada, we continue to take market share. Our advantage in Canada goes well beyond our portfolio breadth, though. It's also our best-in-class technology service, our ability to attract top talent, and the depth of our customer relationships that really differentiates us there. The U.S. dental equipment sales remain on pace for the quarter, given the tough comparable from U.S. dental school orders in the second quarter of last year. We continue to drive sales growth from our exclusive supplier sponsored promotions.

Our backlog remains healthy, and we expect U.S. equipment growth for the rest of the year. International equipment growth was broad-based and continues to be good. The non-acute care U.S. medical market remains solid. Our government-related and Home Health Solutions businesses continue to grow well. Despite lower demand for point-of-care diagnostic tests, our medical business saw good underlying growth. Our specialty product sales were also solid in the quarter.

Overall, implant growth in Europe was high single digits with premium implants led by our Camlog brand, which is the market leader in Central Europe. Value implants led by our Biotec Dental and Medentis brands. We achieved more modest growth in the U.S. where our Tapered Pro conical implant drove positive results, as well as our S.I.N. 360, which was recently launched in the U.S. Finally, sales growth in endodontic products was also good in aggregate across all of our businesses.

Our Global Technology Group business, Henry Schein One, delivered another quarter of strong growth with sustained momentum in cloud-based software and technology solutions. Almost 13,000 customers now subscribe to our Dentrix Ascend and Dentally cloud-based platforms. We're seeing more customers move toward our higher featured packages, which is increasing our monthly revenue per customer. Additionally, approximately 90% of Henry Schein One's revenue is recurring. This creates a highly predictable business model.

By leveraging the data from our market-leading practice management system, we are now broadly embedding AI tools in our software from which our customers are recognizing meaningful benefits. The recent launch of our next generation AI clinical workflow has been met with strong market reception, reinforcing Henry Schein's position at the forefront of the industry's AI transformation. Some examples include our voice-enabled clinical note documentation, our patient insurance eligibility analysis, claims and collection management, as well as clinical diagnosis and treatment analysis.

These new capabilities help to drive productivity for private practice, for group practices, and for DSOs. As dental practice labor costs continue to rise, our customers are looking to Henry Schein to help them operate more efficiently. These technology solutions uniquely position us to address this growing need. A few weeks ago, I spent some time with our Henry Schein One team in Utah, and while I'm excited about the capabilities that we've recently launched, I'm even more confident in the opportunities that are ahead.

Henry Schein One's vision includes expanding AI deeper into the clinical and operational workflows through additional capabilities. I'll make one quick announcement. Coming soon is the launch of an MCP layer that enables practices to query their own data with AI applications and agents. This allows them to identify revenue opportunities as well as to drive further operational efficiencies in a targeted manner. I'll highlight the progress that we've made advancing our strategic plan during the quarter.

Our overall margins expanded, partially driven by our high growth, high margin businesses, which now represent almost 50% of total operating income. We remain on track to exceed our goal of over 50% by the end of our strategic planning cycle in 2027. Our own brands, including our corporate brands, continue to grow well at almost twice the rate of other merchandise sales. Our value creation plans remain a top focus for our team, and we are on track to achieve our goals.

I'd like to go a click deeper and share some of the key initiatives supporting these value creation plans. First, we've selected our global outsourcing provider to support finance and customer service and have begun implementing phase I within our U.S. businesses. We expect to see initial benefits from labor cost efficiencies starting in the third quarter, and we expect this project alone to deliver more than half of the G&A savings in our $200 million goal. Second, we've set up a procurement office to identify preferred suppliers and consolidate indirect spend across our businesses.

This is already yielding results for us. Third, we've started to use our sales data to identify margin opportunities, enabling more dynamic and disciplined pricing, which is helping us expand our gross profits. As we look towards next year, we're planning to implement several new initiatives, including broadening the scope of our outsourcing initiative, expanding our AI capabilities to drive productivity, and implementing new supply chain software to improve efficiencies, reduce inventory, and streamline our purchasing processes.

Each of these products should contribute to additional savings and help us progress toward our goal of double-digit earnings growth next year. I'm encouraged that our momentum continued in the second quarter, and I'm incredibly excited as we transform into the value creation platform for our customers. With that, I'll now turn to Ron to review in more detail our second quarter results and our full year 2026 guidance. Ron?

Thank you, Fred, and good morning, everyone. Today, I will review the financial highlights for the second quarter. We were encouraged by the underlying strength across the business, as demonstrated by some key financial metrics for the quarter, including strong internal local currency sales growth of 4.6%, non-GAAP operating income growth of 10.5%, and non-GAAP earnings per share growth of 15.5%. Starting with our second quarter sales results, global sales were $3.5 billion, with sales growth of 6.7% compared with the second quarter of 2025.

This reflects internal local currency sales growth of 4.6%, a 1.4% increase resulting from foreign currency exchange, and 0.7% sales growth from acquisitions. Our GAAP operating margin for the second quarter of 2026 was 4.94%, an increase of 27 basis points compared with the prior year GAAP operating margin. On a non-GAAP basis, the operating margin for the second quarter was 7.21%, up 25 basis points compared to the prior year, driven by gross margin expansion in all segments. Second quarter 2026 GAAP net income was $94 million, or $0.82 per diluted share.

This compares with prior year GAAP net income of $86 million, or $0.70 per diluted share. Our second quarter 2026 non-GAAP net income was $145 million, or $1.27 per diluted share. This compares with prior year non-GAAP net income of $135 million, or $1.10 per diluted share. Foreign currency exchange favorably impacted our second quarter diluted EPS by approximately $0.01 versus the prior year. We did not record any remeasurement gains in the second quarter of 2026.

This compares with a remeasurement gain of $3.6 million in the second quarter of 2025. Finally, adjusted EBITDA for the second quarter of 2026 was $288 million, compared with second quarter 2025 adjusted EBITDA of $256 million, or 12.7% growth. Turning to our sales results, the components of sales growth for the second quarter are included in Exhibit A in this morning's earnings release. I will now provide the primary highlights of the main sales drivers for each reporting segment.

Global Distribution and Value-Added Services Group sales grew by 6.6%, reflecting good sales momentum across most regions. Looking at the components of that growth, U.S. Dental Merchandise sales grew 8.3%, with 6.5% internal local currency sales growth, resulting from a combination of pricing and increased volume. Our U.S. Dental Merchandise sales growth continues to accelerate. We believe patient traffic remained stable throughout the quarter, that we achieved market share gains.

U.S. Dental Equipment sales declined 1.1%, primarily due to lower traditional equipment sales growth, which was negatively impacted by a few large dental school orders last year. We did experience modest growth in our digital equipment category and expect U.S. Dental Equipment growth for the rest of this year. U.S. Medical Distribution sales grew 3.8% despite continued headwinds in point-of-care diagnostic product sales. We were especially pleased with the growth in our government-related businesses and our Home Solutions business.

International Dental Merchandise sales grew 11.1%, with 5.4% internal local currency sales growth, driven by sales growth in Canada, France, Brazil, and Australia. International Dental Equipment sales grew 8.7%, with internal local currency sales growth of 5.4%. We achieved good sales growth in traditional equipment with modest growth in the digital equipment category. Equipment sales growth was especially good in Canada, Germany, Spain, and the U.K.

Finally, global value-added services sales grew 5.1%, with 3.7% internal local currency sales growth, driven by our business solution services in both the U.S. and internationally, partially offset by lower financial service revenues in the U.S. Turning to the Global Specialty Products Group, sales grew 8.7% with 3.2% internal local currency sales growth. Sales growth was driven by implants and biomaterials in both our premium and value products. Premium implant sales growth continues to be strong in Europe and grew modestly in the U.S. Value implant sales growth was driven by S.I.N. 360 in the U.S. and by our European brands.

Our Global Technology Group also posted good results with total sales growth of 8.2% with 9.1% internal local currency sales growth. In the U.S., we continue to have strong revenue growth in our Dentrix Ascend practice management business. Internationally, sales growth was driven by our Dentally cloud-based practice management software product. Regarding restructuring costs, the company recorded restructuring expenses of $29 million, or $0.18 per diluted share during the second quarter of 2026, as we continued to advance our value creation initiatives.

We continue to expect to achieve our goal of achieving greater than $200 million of operating income improvement resulting from our value creation initiatives, with a $125 million run rate by the end of 2026, and for these projects to continue into the early part of 2028, providing us confidence as we progress toward our goal of double-digit earnings growth. Regarding the operating income improvements in 2026 from our value creation initiatives, we expect approximately 40% of the in-year operating income improvement to originate from the gross profit initiatives and 60% from G&A expense savings.

Beyond 2026, the benefits are expected to be more heavily weighted to G&A savings. Regarding share repurchases, during the second quarter of 2026, the company repurchased approximately 2.6 million shares of common stock at an average price of $76.69 per share, for a total of $200 million. At the end of the quarter, we had approximately $455 million authorized and available for future stock repurchases. Turning to our cash flow, we generated strong operating cash flow of $242 million in the second quarter of 2026, driven by higher net income and working capital management.

Operating cash flow remains on track to exceed net income for the full year. Turning to our 2026 financial guidance, at this time, we are not able to provide, without unreasonable effort, an estimate of restructuring costs, including those related to ongoing value creation initiatives. Therefore, we are not providing GAAP guidance. Our 2026 guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs and other items described in our press release.

Guidance does not include any remeasurement gains for the remainder of 2026 or any future benefits from tariff refunds. Note that total remeasurement gains in FY 2025 were $38 million, and in 2026, we expect total remeasurement gains of $11 million, which was already recorded in the first quarter. Our guidance also assumes that foreign currency exchange rates will remain generally consistent with current levels. Our 2026 total sales growth is now expected to be in the range of 4.5%-5.5% over 2025, compared to our previous guidance of 3%-5%.

This reflects approximately 3.5%-4.5% of expected internal local currency sales growth in the second half of the year, versus actual internal local currency sales growth of 3.6% in the first half of the year, despite a higher prior year comparison in the second half of the year. For 2026, we now expect non-GAAP diluted EPS attributable to Henry Schein, Inc. to be in the range of $5.29-$5.39, reflecting growth of 6%-8% compared to 2025 non-GAAP diluted EPS of $4.97. Our prior guidance was a range of $5.23-$5.37.

This raise in guidance reflects stronger underlying expected sales performance, partially offset by lower remeasurement gains than originally anticipated. Our value creation projects remain on track, and the benefits for the year are unchanged from prior guidance. We expect earnings growth in the fourth quarter to exceed that in the third quarter, reflecting continuing sales momentum and increasing benefits from value creation projects. In addition, as a reminder, we recorded a $28 million remeasurement gain in the third quarter of 2025, which will not recur in 2026.

Regarding taxes, we are assuming an estimated non-GAAP effective tax rate of approximately 24% for the full year, and our 2026 adjusted EBITDA is expected to grow in the mid to high single digits off a base of 2025 adjusted EBITDA of $1.1 billion. With that overview of our business and recent financial results, we're ready to take questions. Operator?

Thank you. We'll now be conducting a question-and-answer session. If you'd like to ask a question, please press star one on your telephone keypad, and a confirmation tone will indicate your line is in the question queue. Let me press star two if you'd like to remove your question from the queue. Participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Thank you. Our first question is from the line of Jeff Johnson with Baird. Please proceed with your question.

Thank you. Good morning, guys, and congratulations on a very solid quarter here. Fred, I wanted to talk just on the U.S. dental consumables market and kind of your performance expectations going forward. I think through the first half of the year, you're just over 4%. Maybe help us understand how much of that do you believe is underlying volume growth versus maybe a combination of price and if you're seeing any increased mix here from some of your manufacturers.

One, just the components of that growth, maybe from a high level. I'm sure you don't want to break it down in great detail. As you do comp into tougher comps in the second half on the U.S. consumables side, how should we think conceptually about that 4% or just north of 4% you put up in the first half? Can we stay around that number against those tougher comps, or just again, conceptually, how would you maybe help us set up our models as we go into the back half of the year? Thank you.

Jeff, thanks for the question. As I think about the consumable growth and merch growth, I would say that, first off, we're excited about the growth that we're seeing. Secondly, we're seeing a little more price than volume. We expect to continue to see a similar range of growth in the second half that we saw in the first half. The comps get a little more difficult, we do expect to see that. What's really driving is really the point here. Last year, we did some promotions starting in the second half of the year, where we really went after some of our episodic customers or customers who were not consistently buying from us.

That promotion and those promotions seemed to really work and where we've really converted many of those customers into actively engaged customers that are continuing to buy from us. We expect to continue to see that in the second half of the year and see that growth rate remain in the same range with the exception of the higher comps that we're seeing.

All right. Next question is from the line of Jason Bednar with Piper Sandler. Please just give us your question.

Hey, good morning. Congrats on another good quarter here, everyone. Ron, I wanted to come to you on the value creation math. Appreciate the additional color today around some of the mix of the contributions. Bigger picture, standing behind the commentary of the $125 million run rate contribution to EBIT exiting this year. Easy math has something like $35 million or better in year-over-year EBIT dollar growth before we even consider organic growth, which is obviously very strong.

Consensus is only modeling something like $10 million in EBIT growth in the second half of the year. I don't know. Maybe an odd question for you, but what do you think is being mismodeled or misunderstood by consensus, by all of us, when, again, you're putting up good results and you stand behind that value creation commitment?

No, thanks for the question, Jason. As we look at the value creation initiatives, our guidance takes into account a range of potential outcomes, but we still believe that we have a good track to achieve that run rate of $125 million of operating income improvements as we exit 2026. A lot of those improvements are going to be realized, the in-year improvements will be realized towards the end of the year, Q3, Q4. As Fred mentioned in the prepared remarks, we've now engaged a third party to help us with what we're internally calling our Global Business Services.

We have other initiatives that are now gaining great traction as we get into the second half of the year. All that is contemplated as we provide the guidance. We'll be able to provide more details in terms of our actual achievements there as we get into, say, the Q3 results as well. Keep in mind also that if you're looking purely at year-over-year results, last year we did have some fairly significant remeasurement gains in the second half of the year, specifically a $28 million gain in the third quarter, that is necessary to normalize for.

As we mentioned, our assumption on guidance for the balance of the year is no further remeasurement gains this year.

Our next question's from the line of Elizabeth Anderson with Evercore ISI. Please proceed with your question.

Hi, guys. Good morning. Congrats on the quarter. Thanks for the question. I was wondering if you could give us a little bit more color on the 40% of cost savings that you said were coming from the gross margin line. Is that sort of split between the pricing initiatives and sort of better growth in sort of higher margin areas? Anything else to consider there? Maybe, Fred, one for you more broadly is if we think about these specialty categories, what are some places where you see further opportunities to accelerate growth as we get into maybe 2026 and beyond that? Thank you.

Yeah. Just on the first one, the 40%, you're exactly right. It includes our initiatives around improving our gross profit, leveraging data better to have a more dynamic view of our pricing, not dynamic pricing, but our pricing is more dynamic and finding opportunities to both raise price where it makes sense and opportunities to lower price where it makes sense in order to drive more volume. Also, as I mentioned earlier, we're seeing really good growth from our corporate brands and our own brands, and that continues to drive our gross profit as well.

Those are the two main drivers there. The second question around specialty, we're excited about the specialty business. One of the things we didn't talk a lot about, but our new products in specialty are really exciting. We expect to see greater growth in specialty, particularly in our implant business as we completed the majority, or took a majority stake in S.I.N. 360 in Q1. We're working to align that strategy. Where we're seeing growth in the U.S. in particular is in the value segment. We believe we have a very good offering there.

We'll see further growth in that value segment. Frankly, we have very leading brands in Europe. We saw really good, strong growth in the implant business in Europe. We're excited about our implant business and excited about the future growth of that from a specialty standpoint.

Our next question is in the line of Allen Lutz with Bank of America. Please proceed with your question.

Good morning. Thanks for taking the question. I want to follow up on Elizabeth's question around the gross margin. Really nice expansion across all three segments, and you talked about 40% of the benefits you're seeing this year coming from gross profit. As we think about the second quarter results, how much of the gross margin expansion benefits are embedded in 2Q? Should we expect more in 3Q, 4Q, or is this the right run rate for the rest of 2026? Thanks.

Hi, Allen. I think that we did see some margin benefit in the second quarter. As we mentioned in the prepared remarks, we're also seeing, for example, better growth in some of our own brands versus third-party brands. Those do carry better gross margins, and that starts to show itself there. I think as we continue to get some growth in specialty and the ongoing growth in the technology segment as well, those obviously are accretive to that overall margin. Within distribution, we're beginning to see some of the early benefits of the value creation initiative.

I think we can build on that as we get into the second half of the year. There's always other factors that come into play in terms of mix. We will expect, for example, better equipment sales in the second half of the year. Equipment sales are typically at a lower margin than merchandise. I think that as we progress in the year, we will continue to see I'll refer to it more as gross profit improvements and gross profit benefits. Sometimes it doesn't always show up in margin percentage, but if it grows our gross profit dollars, we consider that to be what the primary goal is there.

The next question is from the line of Jonathan Block with Stifel. Please proceed with your question.

Hey, guys. Joe Federico on for John. Thanks for taking the question. Maybe just to clarify on the U.S. dental equipment, I know you had tough comps in the quarter due to the one-time dynamics last year. Do you expect year-over-year growth throughout the remainder of the year on a quarterly basis, right? Then maybe just quickly, how are the trends between traditional and digital? We've obviously seen broadly some pressure on digital equipment.

If you can just rehash those dynamics in this quarter and then how you're seeing them play out to date in the second half, that would be great.

Yeah. I'll take the first part, and then I'll let Ron talk about the digital piece. Yeah, you're exactly right. We did have some tougher comps in Q2. We expect to see growth in the next two quarters in equipment. Our bookings look strong, and we feel good about seeing that business grow in the second half of the year. Just on the split between digital and non-digital, I'll let Ron take that.

Yeah, certainly. Joe, I think as you're aware, our equipment business tends to be about two-thirds of it is the traditional equipment. About a third of it is digital. In the U.S., we did see low single-digit growth in digital in the quarter. That's despite some ongoing lower average selling prices, for example, with scanners. We're seeing good volume growth on the scanners. We did get some scanner growth, even though the demand for scanners tends to be more towards the lower price entries in the market as opposed to some of the higher price scanners that are available.

Digital, we got modest growth. I think we can continue with that modest growth going forward. As Fred said on the traditional side, the backlog gives us really good visibility into what we think we can accomplish in the balance of the year, hence the statement that we do expect equipment growth for the rest of the year.

The next question is from the line of John Stansel with JPMorgan. Please proceed with your question.

Great. Just want to drill in on specialty margins that are expanded nicely year-over-year. I think in previous quarters, we've discussed the idea that value implants outgrowing premium implants creates a bit of a margin headwind. Is it fair to say that reversed this quarter, or how are we thinking about the mix contribution from premium versus value in this quarter, and then the durability of that going forward? Thanks.

Hi, John. Yeah. I'll take that one. I think that the margin expansion is an indication of the strength of the premium implants business in Europe right now. We get very good margins on our revenues there. We did see very good growth. The premium implant growth in the U.S. was a little more modest. In Europe, it was quite good. Having said that, we're pleased with the value implant growth in the U.S. as we continue to get some traction and introduce the S.I.N. 360 value implant within the U.S.

I would say the mix had a bit of a shift given the strength of the premium implant business in Europe. We also saw kind of across the board good margins on endodontics and a few other products within that segment as well.

The next question is from the line of Kevin Caliendo with UBS. Please proceed with your question.

Thanks for taking my question. Congrats on a really good quarter. I'm interested, you're talking about specialty in Europe. There's been some questions on it, but the dynamics there, we also saw this from another specialty player, where EMEA was strong and international was strong, and U.S. wasn't. Is this a reflection of Henry Schein's products specifically, or is there something going on in the U.S. market? Is it more just consumer-driven versus EU? I'm just trying to understand why the strength exists in EU and not in the Americas right now for specialty.

Yeah, I think it's a market difference in the U.S. versus in EMEA. I think the market in the U.S. is more consumer-like as it relates to implants relative to what you see in EMEA. We believe we took share in the U.S. market, in the quarter, that is, for our premium implants, and frankly, for implants in general. The market is just not growing as fast in the U.S. as it is in EMEA.

Our next question is from the line of Glen Santangelo with Barclays. Please proceed.

Oh, yeah. Thanks for taking my question. I just wanted to come back to this faster than expected consumable number. In your prepared remarks, I think you sort of suggested that patient volumes continue to be stable, but the better growth was really coming from market share gains, and I was wondering if you could elaborate on that a little bit and give us maybe a better sense for where the market share is coming from. Then, Ron, as you look at the quarterly results, is there any story to tell inter-quarter between April, May, and June, or was the growth pretty ratable throughout the quarter? Thanks.

Yeah. Thanks for the question. The share gain is coming from a couple places. One, our own brands continue to grow faster than our third-party brands, so we're growing there. Secondly, we have a strong position with DSOs, and structurally, we see DSOs growing faster than the rest of the market, so that obviously plays into our growth rate. The third thing is we continue to, as I mentioned earlier, convert customers from being episodic buyers to being actively buying from us consistently. We're seeing growth there.

The final thing is, as I think about some of our exclusive products that we have and others don't, Curadont would be an example, we're seeing good growth from our exclusive products. Those things together allowed us in the quarter to outpace the market, and we expect for that to continue to happen.

Yeah. Glen, regarding the second half of your question, I would say, the second quarter, we saw what I would consider to be a fairly steady, consistent pattern over the course of the quarter. The second quarter, at least within the quarter, tends to be a little more predictable than perhaps what you might see in the first quarter, where you might have weather disruptions or illness disruptions within the market. The second quarter was pretty steady.

I would say we felt like we had a good, strong finish to the quarter, which is always encouraging. For the most part, it was a fairly steady quarter, April, May to June.

The next question's from the line of Brandon Vazquez with William Blair. Please proceed with your question.

Hey, guys. Congrats on a nice quarter, and thanks for the question. Maybe I'll focus on two kind of broader high-level questions because a lot of near-term things have been asked. Fred, as you had mentioned portfolio, I'm not sure if portfolio rationalization or optimization was the exact phrase you used, but maybe spend a second talking to us about what exactly that means. What are you looking for within the portfolio that should or should not be there?

The higher-level question to follow up on that is just, Fred, as you look at this organization, not in one year, but three years out, what do you think the biggest difference is investors should expect given a lot of the changes that are going now, both from an operational and a commercial perspective? Thanks, guys.

Yeah. Thanks for the question. As it relates to the portfolio, we're taking a look at the portfolio. I don't expect major changes to the portfolio, but as we've laid out our priorities are really focused around accelerating growth and driving better returns. We're looking for places in the portfolio that don't line up with that. Will there be some pruning to the portfolio? We'll see, and obviously, we'll let you know what we find going forward. I think secondly, I'll just take that to extend that to what's our thinking on M&A.

I think you'll see us be very disciplined from an M&A perspective and focusing on things that are highly strategic, meaning things that help us continue to build this platform for value creation for our customers. Things that we would be the natural owner of or the rightful owner of in order to support our customers better and things that are going to help us grow faster and deliver really great returns to our shareholders. That's how I'm thinking about the portfolio. As we make decisions around that, we'll obviously get back to you.

As you think about a few years out, we're going to obviously deliver on our commitments short term, but longer term, we expect to see this business accelerate growth and do it more profitably. Ultimately, be positioned less as a distributor, even though we'll be a great distributor for our customers, but really be positioned as the practice improvement platform for our customers, where we're able to help our customers really optimize their businesses, help them grow faster, and help them do it more productively.

That's what we're focused on, is really helping our customers improve their situation. If we do that well, we should be able to reach our goals of accelerating growth and doing them more profitably.

Our next question's from the line of David Larsen with BTIG. Please proceed with your question.

Hi. Congratulations on the really good growth you delivered. Can you talk a little bit more about the AI efforts, Dentrix, the software, the technology? You mentioned you're going to be creating an analyzer solution. How many of your Dentrix customers buy the merch through you, and you're their core distributor? What is the growth potential there? All of that sounds really important to me, because your dentists can basically accelerate their volume growth, which obviously benefits you and them. Just any more color there would be very helpful. Thank you.

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Company Participants